Kymera Therapeutics

Recent news

• J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140
  Market Newswire · 2026/9/28
• Rating change
  J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $121
  Market Newswire · 2026/8/8
• Rating change
  Deutsche Bank Initiates Kymera Therapeutics(KYMR.US) With Hold Rating, Announces Target Price $120
  Market Newswire · 2026/7/30
• Rating change
  Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $132
  Market Newswire · 2026/8/14
• Rating change
  BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $144
  Market Newswire · 2026/9/14
• Rating change
  Analysts' Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)
  TipRanks · 2026/8/11
• Rating change
  Guggenheim Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $135
  Market Newswire · 2026/7/28
• Form 144 | Kymera Therapeutics(KYMR.US) Officer Proposes to Sell 3.35 Million in Common Stocks
  Market Newswire · 2026/10/2
• Rating change
  A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $116 to $139
  Market Newswire · 2026/8/7
• Kymera Therapeutics(KYMR.US) Officer Sells US$3.41 Million in Common Stock
  Market Newswire · 2026/10/2
• Rating change
  Wells Fargo Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $151
  Market Newswire · 2026/8/27
• Rating change
  Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $152
  Market Newswire · 2026/9/22
• Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140
  Market Newswire · 2026/9/23
• Rating change
  BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Cuts Target Price to $123
  Market Newswire · 2026/8/8
• Rating change
  J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $140
  Market Newswire · 2026/9/4
• Rating change
  A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $128 to $139
  Market Newswire · 2026/8/6
• Citi Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $150
  Market Newswire · 2026/10/5
• Rating change
  Wolfe Research Upgrades Kymera Therapeutics(KYMR.US) to Buy Rating, Announces Target Price $180
  Market Newswire · 2026/9/10
• Rating change
  J.P. Morgan Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
  TipRanks · 2026/9/4
• Rating change
  Guggenheim Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $170
  Market Newswire · 2026/8/31

Headlines are aggregated automatically and are not independently verified or edited by our team.